Ponce Aix, SantiagoTalbot, DenisGovindan, RamaswamyDols, Manuel CoboPostmus, Pieter ELewanski, ConradBennouna, JaafarFischer, Juergen RJuan-Vidal, OscarStewart, David JArdizzoni, AndreaBhore, RafiaWolfsteiner, MarianneReck, MartinOng, Teng JinMorgensztern, Daniel2023-02-082023-02-082020-03-31http://hdl.handle.net/10668/15304Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/EORTC QLQ-C30EQ-5D-5Ldurvalumablung cancer symptom scalenab-paclitaxelnon-small cell lung cancerquality of lifeAdultAgedAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedPaclitaxelQuality of LifeRetreatmentTreatment Outcomeresearch article32228198open access10.2217/fon-2019-07961744-8301https://www.futuremedicine.com/doi/pdf/10.2217/fon-2019-0796